Phosphite deoxygenation of steroidal[3,4-c] and [16,17-c] furazan N-oxides

Dharam Paul Jindal*, Ranju Gupta, Inder Bir Singh, J S R A Sharma & M R Yadav

University Institute of Pharmaceutical Sciences[†], Panjab University, Chandigarh

Received 19 March 1996; revised 4 July 1996

 3β -Acetoxy-5-androsteno[16,17-c]-1',2',5'-oxadiazole N-oxide (1), 3-methoxy-1,3-5(10)-estratrieno[16,17-c]-1',2',5'-oxadiazole N-oxide (2), [16,17-c]furoxano-5 α -androstano[3,4-c]furazan (3) and 17 β -acetoxy-5 α -androstano[3,4-c]-1',2',5'-oxadiazole N-oxide (4) have been synthesised to investigate the reactions with triethyl phosphite. The products obtained have been identified. Furazan N-oxide fused to D-ring gives dinitriles 5,6 and 7 whereas furoxan at 3,4-position yield furazan 8.

It is well known that amine oxides¹, azoxy benzene and substituted nitroso benzenes² are deoxygenated by means of trialkyl phosphite. There are also reports that ethylene oxides³, phthalic anhydride⁴ and pyridine-1 oxide⁵ can also be deoxygenated employing *tert*-phosphites. Trialkyl phosphites are also known to deoxygenate nonsteroidal furoxans⁶⁻⁸.

We thought it worthwhile to study the behaviour of triethyl phosphite with steroidal furazan N-oxides 1,2,3 and 4 which we report in this paper. The furoxan (1) was prepared by treating 3β -hydroxy-5-androsteno[16, 17-c]-1',2',5'-oxadiazole N-oxide⁹ with acetic anhydride in pyridine at 100°. The compound **1** showed IR bands at 1735, 1655, 1250 and 1035 cm⁻¹ and UV maximum was at 261 nm. In the ¹H NMR spectrum there appeared singlet at $\delta 2.03$ (3H, $-OCOCH_3$). Compound **1** was refluxed with triethyl phosphite under nitrogen atmosphere to give a dinitrile derivative **5** which showed prominent IR bands at 2240 cm⁻¹. Its ¹H NMR spectrum showed singlets at $\delta 1.05$ and 1.42 for 19methyl and 18-methyl, respectively. A singlet appeared at $\delta 2.05$ for acetoxy function. The α configuration of the tertiary nitrile at Carbon-13 was assigned on the basis of earlier reports^{10,11}.



[†]Formerly Department of Pharmaceutical Sciences.





(6)





The behaviour of triethyl phosphite was further studied in estrone series. Deoxygenation of furoxan derivative 2^9 with triethyl phosphite under the above mentioned_experimental conditions gave 6. IR spectrum showed vibrational bands at 2250 and 2228 cm⁻¹ and ¹H NMR spectrum exhibited three-proton singlets at $\delta 1.47$ (18-CH₃) and 3.70 (-OCH₃). Similarly refluxing 3^{12} with triethyl phosphite under nitrogen atmosphere gave 7. It showed characteristic absorption bands at 2250 cm⁻¹ (C=N) in the IR spectrum. ¹H NMR showed peaks at $\delta 0.80$ (s, 3H, 19-CH₃), 1.53 (s, 3H, 18-CH₃) and 2.77 (m, 2H, 15-CH₂).

It is interesting to note the deoxygenation with triethyl phosphite of furazan N-oxide 4^{13} fused to six membered ring, which on heating under reflux under similar conditions with triethyl phosphite gave a furazan 8^{13} . ¹H NMR spectrum exhibited singlets at $\delta 0.77$ (s, 3H, 18-CH₃), 0.82 (s, 3H, 19-CH₃) and 2.05 (s, 3H, OCOCH₃)¹³.

These observations lead us to confirm the suggested mechanism for the deoxygenation with triethyl phosphite under forcing conditions [refluxing with $(C_2H_5O)_3P$]¹⁴.

It is observed in this study that furazan fused to another five membered ring D is under strain¹⁴ and there is ring opening giving dinitriles, whereas furazan fused to six membered ring A of steroid skeleton has the greater thermodynamic stability and does not result in the formation of dinitriles. We made unsuccessful attempts to prepare the steroidal[16,17-*c*]-1',2',5'-oxadiazole through this route from [16,17-*c*]-1',2',5'-oxadiazole N-oxide or refluxing 16,17-dioximino-5-androsten-3 β -ol with potassium hydroxide and ethylene glycol.

Experimental Section

Melting points reported are uncorrected. ¹H NMR spectra (90 MHz) were recorded in CDCl₃ containing TMS as internal reference (chemical shifts in δ , ppm), IR spectra in KBr (ν_{max} in cm⁻¹) and UV spectra in methanol (λ_{max} in nm, figures within parentheses refer to log ε values). Mass spectra were recorded on Vg-11-250J 70S model. Elemental analyses were carried out on Perkin-Elmer-2400 model.

 17β -Acetoxy- 5α -androstano[3, 4-c]-1', 2', 5'oxadiazole N-oxide (4). 3,4-Dioximino-5ξandrostan-17 β -ol¹⁵ (1g) was dissolved in a mixture of ethanol (10 mL) and aq. NaOH (20%, 3 mL) and chilled. Freshly prepared sodium hypochlorite solution (8 mL) was added to the above chilled and stirred solution. The reaction mixture was kept at 0° for 24 hr, poured into ice-cold water, filtered, washed and dried. The residue so obtained was crystallised from ethanol to yield 17β -hydroxy- 5α -androstano[3,4-c]-1',2',5'-oxadiazole N-oxide (0.65 g, 65.4%), m.p. 208-10°; UV (MeOH): 261 (3.92); IR: 1635, 1475, 1175, 1075; ¹H NMR: 0.78 (s, 6H, 18-CH₃ and 19-CH₃), 3.67 (t, 1H, 17 α -H) (Found : C, 68.40; H, 8.44; N, 8.19. C₁₉H₂₈N₂O₃ requires C, 68.64; H, 8.48; N, 8.42%).

 17β -hydroxy- 5α -androstano[3,4-c]-1',2',5'-oxadiazole N-oxide (1 g), was dissolved in acetic anhydride (2 mL) and pyridine (5 mL) and heated on water bath for 1 hr. After cooling, the reaction mixture was poured into crushed ice. The precipitate was filtered, washed off free from pyridine and dried. The product was crystallised from methanol to yield 4 (0.8 g, 71%), m.p. 221-22°; UV (MeOH): 261 (3.79); IR : 1725, 1630, 1460, 1240, 1035; ¹H NMR : 0.78 (s, 3H, 19-CH₃), 0.82 (s, 3H, 18-CH₃), 2.05 (s, 3H, -OCOCH₃), 4.70 (m, 1H, 17 α -H) (Found : C, 67.59; H, 8.30; N, 7.44. C₂₁H₃₀N₂O₄ requires C, 67.35; H, 8.07; N, 7.48%).

 3β -Acetoxy-16,17-seco-5-androsten-16, 17-di- 3β -Acetoxy-5-androsteno[16,17-c]nitrile (5). 1',2',5'-oxadiazole N-oxide (1) (0.5 g) was refluxed in triethyl phosphite (10 mL) for 15 min under nitrogen atmosphere. The reaction mixture was poured into ice-cold water and made acidic with dil. H₂SO₄. The precipitated material was filtered, washed and dried. The product was crystallised from methanol to yield 5 (0.35 g, 76.6%), m.p. 175-76°; IR: 2240, 2260, 1710, 1360, 1260, 1040, 1030; ¹H NMR : 1.05 (s, 3H, 19-CH₃), 1.42 (s, 3H, 18-CH₃), 2.05 (s, 3H, -OCOCH₃), 2.72 (d, 2H, 15-CH₂), 4.60 (m, 1H, 3-CH), 5.40 (m, 1H, 6-CH) (Found: C, 73.68; H, 8.35; N, 7.78. C₂₁H₂₈N₂O₂ requires C, 74.08; H, 8.29; N, 8.23%).

3-Methoxy-16, 17-seco-1, 3, 5(10)-estratriene-16,17-dinitrile (6). 3-Methoxy-1,3,5(10)-estratrieno[16,17-*c*]-1',2',5'-oxadiazole N-oxide (**2**)⁹ (0.3 g) was treated as above to give **6** (0.2 g, 74.1%) m.p. 142-44°; UV: 230 (3.69), 277 (3.28), 285.6 (3.24); IR: 2945, 2250, 2228, 1613, 1574, 1501, 1460, 1432, 1283, 1140, 1045; ¹H NMR: 1.47 (s, 3H, 18-CH₃), 3.70 (s, 3H, - OCH₃), 6.60 (s, 1H, 4-CH), 6.70 (d, 1H, 2-CH), 7.06 (d, 1H, 1-CH); MS: m/z 294 (M⁺) (Found: C, 77.21; H, 7.76; N, 9.33. C₁₉H₂₂N₂O requires C, 77.52; H, 7.53; N, 9.52%).

16, 17-Seco-5 α -androstano[3, 4-c]-1',2',5'-oxadiazole-16,17-dinitrile (7). [16,17-c]Furoxano-5 α -androstano[3,4-c]furazan (3)¹² (0.1 g) was treated as above to afford 7 (0.055 g, 50%), m.p. 206-07°; UV: 212 (3.65); IR: 2250, 1490, 1425, 1395, 1025, 945; ¹H NMR: 0.80 (s, 3H, 19CH₃), 1.53 (s, 3H, 18-CH₃), 2.77 (m, 2H, 15-CH₂) (Found: C, 67.13; H, 6.44; N, 16.24. $C_{19}H_{24}N_4O.H_2O$ requires C, 66.64; H, 7.65; N, 16.36%).

17β-Acetoxy-5α-androstano [**3**,**4**-*c*]-**1**',**2**',**5**'-oxadiazole (8). 17β-Acetoxy-5α-androstano[**3**,**4**-*c*]-1',2',5'-oxadiazole N-oxide (**4**) (0.2 g) was treated as above to yield **8**¹³ (0.11 g, 57.5%), m.p. 177.78° (lit. 174-76°); UV: 222 (3.61); IR: 1730, 1445, 1390, 1255, 1055, 1040, 875; ¹H NMR: 0.77 (s, 3H, 18-CH₃), 0.82 (s, 3H, 19-CH₃), 2.05 (s, 3H, $- \text{OCOCH}_3$), 4.70 (m, 1H, 17-CH); MS: m/z 358 (M⁺) (Found: C, 70.52; H, 8.86; N, 7.73. C₂₁H₃₀N₂O₃ requires C, 70.35; H, 8.43; N, 7.82%).

Acknowledgement

We are grateful to CIPLA, Bombay for supplying DHA acetate, to M/s Schering Aktiengesell Schaft, Berlin, Germany for the generous supply of estrone methyl ether and to the Panjab University and UGC for financial assistance.

References

- 1 Howard Jr E & Olszewski W F; J Am Chem Soc, 81, 1959, 1483.
- 2 Horner L & Hoffmann H, Angew Chem, 68, 1956, 473.
- 3 Scott C B, J Org Chem, 22, 1957, 1118.
- 4 Ramirez F, Yamanaka H & Basedow O H, J Am Chem Soc, 83, **1961**, 173.
- 5 Hamana M, J Pharm Soc, Japan, 75, 1955, 121.
- 6 Mukaiyama T, Nambu H & Okamoto M, J Org Chem, 27, 1962, 3651.
- 7 Grundmann C, Chem Ber, 97, 1964, 575.
- 8 Bailey A S & Evans J M, Chem Ind, 1964, 1424.
- 9 Reimann H & Schneider H, Can J Chem, 46, 1968, 77.
- 10 Hassner A & Pomerantz I H, J Org Chem, 27, 1962, 1760.
- 11 Regan B M & Hayes F N, J Am Chem Soc, 78, 1956, 639.
- 12 Jindal D P, Gupta R, Singh I B, Sharma N & Yadav M R, Indian J Chem, 34B, 1995, 560.
- 13 Yadav M R, Abraham J & Jindal D P, Indian J Chem, 29B, 1990, 26.
- 14 Boulton AJ & Mathur S S, J Org Chem, 38, 1973, 1054.
- 15 Singh H, Yadav M R & Jindal D P, Indian J Chem, 26B, 1987, 95.